| 1 |
Skvortsova EV, Nazarov IB, Tomilin AN, Sinenko SA. Dual Mode of Mitochondrial ROS Action during Reprogramming to Pluripotency. Int J Mol Sci 2022;23:10924. [PMID: 36142834 DOI: 10.3390/ijms231810924] [Reference Citation Analysis]
|
| 2 |
McKnight CL, Low YC, Elliott DA, Thorburn DR, Frazier AE. Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned? Int J Mol Sci 2021;22:7730. [PMID: 34299348 DOI: 10.3390/ijms22147730] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 3 |
Braverman-Gross C, Benvenisty N. Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements. Front Endocrinol (Lausanne) 2021;12:622940. [PMID: 33692757 DOI: 10.3389/fendo.2021.622940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Okano H, Sipp D. New trends in cellular therapy. Development 2020;147:dev192567. [PMID: 32943426 DOI: 10.1242/dev.192567] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 5 |
Matsui T, Miyamoto N, Saito F, Shinozawa T. Molecular Profiling of Human Induced Pluripotent Stem Cell-Derived Cells and their Application for Drug Safety Study. Curr Pharm Biotechnol 2020;21:807-28. [PMID: 32321398 DOI: 10.2174/1389201021666200422090952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 6 |
Kamal MM, Kassem DH. Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges. Front Cell Dev Biol 2020;8:16. [PMID: 32064260 DOI: 10.3389/fcell.2020.00016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 7 |
Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshirylajimi A. Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges. Adv Exp Med Biol 2021;1312:19-37. [PMID: 33159303 DOI: 10.1007/5584_2020_592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 8 |
Bandeiras C, Hwa AJ, Cabral JMS, Ferreira FC, Finkelstein SN, Gabbay RA. Economics of Beta-Cell Replacement Therapy. Curr Diab Rep 2019;19. [DOI: 10.1007/s11892-019-1203-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
